Axovant Gene Therapies Ltd (NASDAQ:AXGT)

3.36
Delayed Data
As of Aug 11
 +0.165 / +5.17%
Today’s Change
1.41
Today|||52-Week Range
8.08
-34.47%
Year-to-Date
AAAPL, FB among premarket gainers
Jul 31 / Seeking Alpha - Paid Partner Content
Axovant signs gene therapy supply deal with Oxford Biomedica
Jul 31 / Seeking Alpha - Paid Partner Content
AAPL, FB among premarket gainers
Jul 31 / Seeking Alpha - Paid Partner Content
 

Today’s Trading

Previous close3.19
Today’s open3.25
Day’s range3.14 - 3.44
Volume31,708
Average volume (3 months)223,688
Market cap$122.2M
Data as of 3:59pm ET, 08/11/2020

Growth & Valuation

Earnings growth (last year)+63.48%
Earnings growth (this year)+35.20%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book1.95

Competitors

 Today’s
change
Today’s
% change
LUMOLumos Pharma Inc-1.00-6.46%
CKPTCheckpoint Therapeut...-0.05-2.33%
MNKMallinckrodt PLC-0.10-7.00%
GNPXGenprex Inc-0.20-5.25%
Data as of 4:31pm ET, 08/11/2020

Financials

Last reporting dateAugust 11, 2020
EPS forecast (this quarter)-$0.49
Annual revenue (last year)$0.00
Annual profit (last year)-$72.6M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
London, London & South East

Forecasts